Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created…
Modeyso™ (Dordaviprone) Gains Inclusion in NCCN Clinical Practice Guidelines, Marking a Milestone in the Treatment of H3 K27M-Mutant Diffuse Glioma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced a pivotal development for its oncology portfolio with the inclusion of Modeyso™ (dordaviprone) in…
Novartis to Acquire Tourmaline Bio, Advancing Cardiovascular Pipeline with Pacibekitug for ASCVD Novartis today revealed a major step forward in its cardiovascular disease (CVD) strategy with the announcement that it has entered into an agreement to acquire Tourmaline Bio, Inc.…
Cascade Bio Secures $6 Million to Advance Biocatalyst Innovation and Transform Biomanufacturing In a world grappling with climate change, supply chain disruptions, and the growing demand for sustainable manufacturing, biotechnology companies are racing to create alternatives to petrochemical-based production. Cascade…
RION Launches INTENT Biologics to Advance Late-Stage Clinical Exosome Therapies in Inflammation & Immunology; Appoints Industry Leader Suneet Varma as CEO RION, a clinical-stage regenerative medicine company recognized globally for its pioneering work in exosome-based therapeutics, has announced the formation…
JCR Pharmaceuticals Showcases Landmark Five-Year Clinical Data on Pabinafusp Alfa at ICIEM 2025, Reinforcing Transformative Potential for Patients with Hunter Syndrome and Expanding Pipeline of Brain-Penetrant Enzyme Replacement Therapies In early September 2025, the city of Kyoto, Japan, became the…
Tolerance Bio and ZipCode Bio Forge Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics In a landmark move that underscores the growing intersection of immunology and RNA-based medicine, Tolerance Bio, a young biopharmaceutical company dedicated to extending healthspan by preserving…
FDA Expands Approval of Takeda’s VONVENDI®, First Recombinant von Willebrand Factor Therapy, to Include Routine Prophylaxis for Adults and Children with von Willebrand Disease Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), a global biopharmaceutical leader with a longstanding commitment to advancing therapies…
Genentech Presents New Long-Term Data for Vabysmo in Wet AMD and PCV at Euretina Congress 2025 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced compelling new data from two important clinical studies evaluating Vabysmo®…
SCIEX Expands BioPhase 8800 Capabilities with Native Fluorescence Detection to Advance Protein-Based CE Assays At the 2025 CE Pharm conference, SCIEX, a global leader in life science analytical technologies, announced the launch of native fluorescence detection on its flagship BioPhase…
Octave Bioscience Secures $35.6 Million Series C Financing and $15.5 Million Loan to Accelerate Growth and Advance Precision Care in Neurology Octave Bioscience, Inc., a commercial-stage precision care company dedicated to transforming the management of neurodegenerative diseases, has announced a…
MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for patients and families affected by ultra-rare lysosomal storage disorders, MEDIPAL…